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on the Visual Function Questionnaire – Utility Index and subsequent mapping to 
BCVA. Both costs (2012 Canadian dollars) and outcomes were discounted (5%). A 
Canadian panel of clinical experts in the treatment of CRVO validated the model 
structure and resource utilization. One-way and probabilistic sensitivity analyses 
(PSAs), were performed to test the robustness of the model to variations in key 
inputs. RESULTS: The resulting incremental cost-utility analysis (ICUR) was 
$21,568 and $14,103 from the public payer and societal perspective, respectively, 
for OZURDEXTM versus observation. Results of the one-way and multivariate 
analysis suggest that the results were robust. Throughout the 1,000 iterations  
of the PSA the ICUR consistently fell below a willingness-to-pay threshold of 
$50,000/QALY gained. Although robust, the model was most sensitive to age  
of entry and the utilities used for both the best-seeing eye and worst-seeing  
eye. CONCLUSIONS: Based on a willingness-to-pay threshold of $50,000/QALY 
gained, OZURDEX™ is a cost-effective treatment for CRVO compared with 
observation.  
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PATIENTS WITH MODERATE TO SEVERE PSORIASIS  
Zhao M1, Wu J1, Zheng M2, Zheng ZZ3, Yue N4 
1Tianjin University, Tianjin, China, 2Second Affiliated Hospital Zhejiang University College of 
Medicine, Hangzhou, China, 3Huashan Hospital, Fudan University, Shanghai, China, 4Johnson & 
Johnson, Beijing, China  
OBJECTIVES: To validate and compare the psychometric properties of two 
generic preference-based HRQoL instruments, EuroQol (EQ-5D) and Short-Form 
6D (SF-6D) among psoriasis patients in China. METHODS: Validity of the EQ-5D 
and SF-6D was examined with the patients in conjunction with Dermatology Life 
Quality Index (DLQI). Responsiveness was tested using the effect size (ES), 
relative efficiency (RE) and receiver operating characteristic (ROC) curves. 
Agreement between EQ-5D and SF-6D was tested using intra-class correlation 
coefficient (ICC) and Bland-Altman plot. RESULTS: A total of 150 moderate to 
severe patients were included with 50% female, mean age of 43.87 and mean 
disease duration of 5.19 years. The mean utility scores (SD) were 0.64 (0.32) for 
EQ-5D and 0.72(0.12) for SF-6D. There were no serious floor effects for EQ-5D and 
SF-6D but large ceiling effects for EQ-5D existed. Validity was demonstrated by 
the moderate to strong correlation coefficients (range: 0.50-0.71, P<0.001) for six 
of the ten hypotheses in both instruments. Both of EQ-5D and SF-6D showed a 
well discriminative capacity similarly (ES=0.98-1.27, ES=0.99-1.26) between 
groups with different psoriasis specific health status. RE showed that SF-6D 
(6.00-39.00%) was more efficient than EQ-5D in three domains of DLQI  
(recreation, relationships and treatment). Conversely, SF-6D (−1.00 - −13.00%) was 
less efficient than EQ-5D in three domains of DLQI (symptoms and feelings, daily 
activities and work and studies). The areas under ROC of them all exceeded  
0.5 (0.71- 0.84, P<0.001). Poor agreement between them was observed with  
ICC (0.38, P<0.001) and Bland-Altman plot analysis. CONCLUSIONS: This  
study provides evidence that EQ-5D and SF-6D are valid and sensitive 
preference-based HRQoL instruments in Chinese patients with moderate to 
severe psoriasis. SF-6D may be a more effective tool with lower ceiling effect. 
Further study is needed to compare other properties, such as reliability and 
longitudinal response.  
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OBJECTIVES: To assess health utilities and examine factors affecting health utilities 
among patients with moderate to severe psoriasis in China. METHODS: Data were 
obtained from a cross-sectional HRQoL survey of psoriasis patients in 29 tertiary 
hospitals of 7 cities in China from June to July, 2012. Eligible patients were assessed 
with moderate to severe psoriasis by physicians and treated with prescriptions 
during the visit/hospitalization. Degree of moderate and severe was estimated by 
physicians based on definition of BSA score 3-10% and >10%. Participants 
completed HRQoL measures of EuroQol 5 domains (EQ-5D), Short Form 6 domains 
(SF-6D) and Dermatology Life Quality Index (DLQI). Socio-demographic and 
treatment satisfaction information were also collected from the participants. Mean 
scores were compared and stepwise multivariate linear regression was conducted 
to assess factors associated with health utilities. RESULTS: A total of 150 patients 
were included with 50% female, mean age of 43.87 years and mean disease duration 
of 5.19 years. About 22.67% patients reported having at least one comorbidity with 
anxiety/depression (14.00%) and related infection (10.00%) listed on the top. 36.67% 
patients expressed dissatisfaction with their current treatment. Mean EQ-5D,  
EQ-VAS, SF-6D and DLQI scores were 0.64, 63.23, 0.72 and 11.09, respectively, with 
significant difference between the severe and moderate group in all measures(0.50 
vs. 0.77, 58.12 vs. 67.48, 0.67 vs.0.75, 14.43 vs. 8.33, all p<0.001). Regression analysis 
indicated that health severity indicated by DLQI score was significantly associated 
with value scores of EQ-5D, EQ-VAS, SF-6D. Sleeplessness and living in Tier 1st city 
decreased EQ-5D and SF-6D scores and treatment dissatisfaction had the negative 
impact on EQ-VAS and SF-6D scores with statistic significant. CONCLUSIONS: 
Compared with moderate patients, patients with severe psoriasis have poorer 
health utilities. Increasing the patients’ satisfaction with their treatment and 
controlling insomnia may raise their health utilities effectively.  
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OBJECTIVES: Psoriasis (PsO) is a systemic, inflammatory disease manifesting in 
the skin and associated with psoriatic arthritis. The objective of this study was to 
describe and quantify patients’ disease experiences, including symptoms and 
impact on daily lives and function. METHODS: This observational study was 
conducted in patients with moderate-to-severe PsO across 8 US sites. Qualitative 
data were obtained through semi-structured face-to-face interviews, including 
open-ended questions and patients’ ranking of bothersome symptoms. 
Quantitative data were captured using a case report form addressing 
demographic and clinical characteristics and standard measures of disease 
severity. Each interview was transcribed and thematically coded; all mentions of 
symptoms and areas of life-impact were quantified. Qualitative (ATLAS.ti) and 
quantitative (SAS) software analysis tools were used. RESULTS: A total of 101 
patients participated. Mean age was 49 years (SD = 14), mean duration of disease 
was 19 years, and 54% were male. Patients averaged 15% of body surface area 
involved with PsO. Mean Psoriasis Area and Severity Index score was 8.7 (SD = 
8.0) and 46% of patients were receiving biologic therapy. The most frequent 
patient-reported symptoms were flaking/scaling (non-scalp areas) (90%), 
itching/scratching (88%), rash (75%), flaking/scaling (scalp area) (63%), skin pain 
(63%), skin bleeding (59%), and redness (58%). Most bothersome symptoms were 
itching/scratching, flaking/scaling (non-scalp areas), and skin pain. Nearly all 
patients reported an emotional (98%) and social (95%) life-impact. Other impacts 
included family (74% of patients), professional (69%), physical (52%), educational 
(23%), and sexual (21%). Positive and negative treatment-related experiences 
were reported. CONCLUSIONS: Results provide a detailed description of PsO 
symptoms and identify important targets for treatment based on the patient 
perspective. PsO has a significant multidimensional impact on patients’ lives. 
Recording patient interviews and coding the themes, symptoms, and impacts of 
PsO provide rich material for analysis of patients’ health-related quality of life.  
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OBJECTIVES: Patient reported outcomes (PRO) are becoming useful tools for 
collecting and generating evidence for new medical products to show 
improvements in health-related quality of life (HRQoL). Glaucoma is a chronic 
disease with high importance for patient HRQoL. The objective of this study was 
to review, analyze, and understand trends in the PRO instruments used in 
patients with Glaucoma. METHODS: A systematic literature search for Glaucoma 
trials with PROs endpoints was undertaken for the databases Pubmed, Embase, 
Biosis, Google Scholar and Cochrane. Data was collected for the study size, 
interventions, year, PRO instrument and results for PROs. Analysis for conducted 
to identify trends in commonly used PRO instruments and categorize results as 
positive, neutral or negative. RESULTS: Thirty-one studies with a total of 9819 
patients were identified. In these studies there were eleven different PROs 
instruments were identified that were Glaucoma health perception index, 
Glaucoma quality of life questionnaire (Glau-QoL), Glaucoma utility index, 
Impact of vision impairment, Low vision quality of life questionnaire, National 
eye institute visual function index-19 items, National eye institute visual 
function index-51 items, Nursing home vision quality of life questionnaire, 
Quality of life and visual function questionnaire, Vision core module 1, and 
Vision quality of life index. The most commonly used instruments were Impact 
of vision impairment (used in 7 studies) and Low vision quality of life 
questionnaire (used in 4 studies). CONCLUSIONS: Patients with glaucoma have 
significant impairment in their QoL, hence collection of such data is important 
for new medical products. PRO instruments such as Impact of vision impairment 
and Low vision quality of life questionnaire have been commonly used to 
generate evidence to show which therapies improve patient QoL.  
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OBJECTIVES: To develop a conceptual framework of functional reading 
independence to support development of a patient-reported outcome (PRO) 
measure for patients with geographic atrophy (GA) from age-related macular 
degeneration. METHODS: The conceptual framework was developed based  
on a literature review, expert opinion and patient input. Patient input was 
gathered in a qualitative concept elicitation study with 23 GA patients, where 
functional reading independence emerged as the most relevant concept. A draft 
conceptual framework and PRO questionnaire (interviewer-administered) were 
developed. Cognitive interviews were then conducted with 17 additional  
GA patients to assess understanding, completeness and relevance of the concept 
